Expression of IL-7RαlowCX3CR1+ CD8+ T Cells and α4β7 Integrin Tagged T Cells Related to Mucosal Immunity in Children with Inflammatory Bowel Disease
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: The study aimed to investigate the recruiting of T lymphocytes including IL-7Rαlow CX3CR1+ effector memory (EM) CD8+ T cells and α4β7 integrin tagged T cells to inflamed intestinal mucosa. Methods: Whole blood and mucosal tissues of intestine were collected from 40 children with or without inflammatory bowel disease (IBD). T cell surface staining and immunohistochemistry were done with several antibodies in peripheral blood mononuclear cells (PBMCs) and intestinal mucosa, respectively. Serum levels of cytokines were measured by ELISA. Results: The frequency of IL-7RαlowCX3CR1+ EM CD8+ T cells in the PBMC was significantly higher in the ulcerative colitis group than in the control group (57.9±17.80% vs. 33.9±15.70%, p=0.021). The frequency of integrin α4β7+ CD4+ T cells in the PBMC was significantly lower in the ulcerative colitis group than in the control group (53.2±27.6% vs. 63.9±13.2%, p=0.022). Serum concentration of TNF-α was higher in the Crohn’s disease group than in the control group (26.13±5.01 pg/mL vs. 19.65±6.07 pg/mL, p=0.008). Of the three groups, the ulcerative colitis group had the highest frequency of integrin α4β7+ T cells based on immunohistochemistry analyses for intestinal tissues, followed by the Crohn’s disease group and the control group (4.63±1.29 cells vs. 2.0±0.57 cells vs. 0.84±0.52 cells, p<0.001). Conclusion: Trafficking immune cells with effector memory CD8+ T cells clarified by IL-7RαlowCX3CR1+ and integrin α4β7+ CD4+ T cells might be highly associated with the pathogenesis of ulcerative colitis.
Abstract
Purpose: The study aimed to investigate the recruiting of T lymphocytes including IL-7Rαlow CX3CR1+ effector memory (EM) CD8+ T cells and α4β7 integrin tagged T cells to inflamed intestinal mucosa. Methods: Whole blood and mucosal tissues of intestine were collected from 40 children with or without inflammatory bowel disease (IBD). T cell surface staining and immunohistochemistry were done with several antibodies in peripheral blood mononuclear cells (PBMCs) and intestinal mucosa, respectively. Serum levels of cytokines were measured by ELISA. Results: The frequency of IL-7RαlowCX3CR1+ EM CD8+ T cells in the PBMC was significantly higher in the ulcerative colitis group than in the control group (57.9±17.80% vs. 33.9±15.70%, p=0.021). The frequency of integrin α4β7+ CD4+ T cells in the PBMC was significantly lower in the ulcerative colitis group than in the control group (53.2±27.6% vs. 63.9±13.2%, p=0.022). Serum concentration of TNF-α was higher in the Crohn’s disease group than in the control group (26.13±5.01 pg/mL vs. 19.65±6.07 pg/mL, p=0.008). Of the three groups, the ulcerative colitis group had the highest frequency of integrin α4β7+ T cells based on immunohistochemistry analyses for intestinal tissues, followed by the Crohn’s disease group and the control group (4.63±1.29 cells vs. 2.0±0.57 cells vs. 0.84±0.52 cells, p<0.001). Conclusion: Trafficking immune cells with effector memory CD8+ T cells clarified by IL-7RαlowCX3CR1+ and integrin α4β7+ CD4+ T cells might be highly associated with the pathogenesis of ulcerative colitis.
참고문헌 (20)
- Abraham C, "Inflammatory bowel disease", N Engl J Med, 361, pp.2066~2078 (2009)
- Perez-Lopez A, "Mucosal immunity to pathogenic intestinal bacteria", Nat Rev Immunol, 16, pp.135~148 (2016)
- Zundler S, "Immune cell trafficking and retention in inflammatory bowel disease : mechanistic insights and therapeutic advances", Gut, 68, pp.1688~1700 (2019)
- Sandborn WJ, "Vedolizumab as induction and maintenance therapy for Crohn’s disease", N Engl J Med, 369, pp.711~721 (2013)
- Feagan BG, "Vedolizumab as induction and maintenance therapy for ulcerative colitis", N Engl J Med, 369, pp.699~710 (2013)
- Panés J, "Past, present and future of therapeutic interventions targeting leukocyte trafficking in inflammatory bowel disease", J Crohns Colitis, 12(suppl 2), pp.S633~40 (2018)
- Sans M, "Enhanced recruitment of CX3CR1+ T cells by mucosal endothelial cell-derived fractalkine in inflammatory bowel disease", Gastroenterology, 132, pp.139~153 (2007)
- Chang JT, "Pathophysiology of inflammatory bowel diseases", N Engl J Med, 383, pp.2652~2664 (2020)
- Meenan J, "Altered expression of alpha 4 beta 7, a gut homing integrin, by circulating and mucosal T cells in colonic mucosal inflammation", Gut, 40, pp.241~246 (1997)
- Ledder O, "Vedolizumab in paediatric inflammatory bowel disease : a retrospective multi-centre experience from the Paediatric IBD Porto Group of ESPGHAN", J Crohns Colitis, 11, pp.1230~1237 (2017)
- Shin MS, "DNA methylation regulates the differential xpression of CX3CR1 on human IL-7Rαlow and IL-7Rαhigh effector memory CD8+ T cells with distinct migratory capacities to the fractalkine", J Immunol, 195, pp.2861~2869 (2015)
- Kim HR, "Altered IL-7Rα expression with aging and the potential implications of IL-7 therapy on CD8+ T-cell immune responses", Blood, 107, pp.2855~2862 (2006)
- Kim HR, "Down-regulation of IL-7Rα expression in human T cells via DNA methylation", J Immunol, 178, pp.5473~5479 (2007)
- Yang DH, "Effector memory CD8+ and CD4+ T cell immunity associated with metabolic syndrome in obese children", Pediatr Gastroenterol Hepatol Nutr, 24, pp.377~383 (2021)
- Matsuoka K, "Phase 1 study on the safety and efficacy of E6011, antifractalkine antibody, in patients with Crohn’s disease", J Gastroenterol Hepatol, 36, pp.2180~2186 (2021)
- Neurath MF, "Cytokines in inflammatory bowel disease", Nat Rev Immunol, 14, pp.329~342 (2014)
- Tokita K, "Long-term efficacy and safety of golimumab for ulcerative colitis in a pediatric inflammatory bowel disease center in Japan", Pediatr Gastroenterol Hepatol Nutr, 25, pp.461~472 (2022)
- Wang S, "Integrin α4β7 switches its ligand specificity via distinct conformer-specific activation", J Cell Biol, 217, pp.2799~2812 (2018)
- Dotan I, "The role of integrins in the pathogenesis of inflammatory bowel disease : approved and investigational anti-integrin therapies", Med Res Rev, 40, pp.245~262 (2020)
- Souza HS, "Expression of lymphocyte-endothelial receptor-ligand pairs, α4β7", MAdCAM-1 and OX40, Gut, pp.1999, 45[DOI]